Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06167265 · ClinicalTrials.gov registry record · Phase 1
BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers
A Phase 1 study, sponsored by Genovate Biotechnology Co., Ltd.,.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT06167265: Completed Phase 1 study, sponsored by Genovate Biotechnology Co., Ltd.,.
NCT06167265 is a Phase 1 study that has completed, run by Genovate Biotechnology Co., Ltd.,. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06167265, a Phase 1 study, has completed, sponsored by Genovate Biotechnology Co., Ltd.,.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of immediate- release tablet of cilostazol (Cilostazol) administered twice-daily in normal healthy male and female subjects under fasting conditions.
Interventions
- DRUG Cilostazol Tablet 100 mg
- DRUG PMR Tablet 145 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-11-28 |
| Est. Completion | 2024-01-18 |
| Phase | Phase 1 |
What the finished NCT06167265 record still lists
NCT06167265 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 2 interventions - of which Cilostazol Tablet 100 mg is the first listed.
NCT06167265 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06167265 about?
NCT06167265 is a clinical study titled "BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers". The study is designed to evaluate the bioequivalence and the within-subject variability between the test formulation of extended-release tablet of cilostazol (PMR) administered once daily and the reference formulation of immediate- release tablet of cilostazol (Cilostazol) administered twice-daily i...
What is the current status of trial NCT06167265?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-11-28. Estimated completion is 2024-01-18.
What interventions are being tested in trial NCT06167265?
The interventions under investigation include: Cilostazol Tablet 100 mg (DRUG), PMR Tablet 145 mg (DRUG).
Who is sponsoring clinical trial NCT06167265?
This trial is sponsored by Genovate Biotechnology Co., Ltd.,, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06167265's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI